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1. Introduction 
Chitin (┚-1,4-D-linked polymer of N-acetylglucosamine) is a naturally abundant 
mucopolysaccharide and is second to cellulose in terms of the amount produced annually 
by biosynthesis. Chitin is visually characterized as a white, hard, inelastic, nitrogenous 
polysaccharide, and approximately one billion tons are synthesized each year (Peter, 1997). 
Chitin is a common constituent of the exoskeleton in animals, particularly in crustaceans, 
mollusks and insects. Commercially sold chitin is usually extracted from shellfish waste 
(Skjak-Braek et al., 1989; Goosen, 1997). Chitin is structurally similar to cellulose; however 
less attention has been paid to chitin than cellulose, primarily due to its inertness. Hence, it 
remains an essentially unutilized resource. Deacetylation of chitin yields chitosan, which is a 
relatively reactive compound and is produced in numerous forms, such as powder, paste, 
film and fiber. 
Chitosan is a poly-(┚-1, 4-D-glucosamine) derived from the N-deacetylation of chitin (Figure 
1). It is soluble in dilute aqueous acetic, lactic, malic, formic and succinic acids. Chitosan 
may be fully or partially N-deacetylated, but the degree of acetylation is typically less than 
0.35. The acetylation ratio is defined by a variety of methods, including pyrolysis gas 
chromatography, gel permeation chromatography and ultra-violet (UV) spectrophotometry, 
titration, separation spectrometry and near-infrared spectroscopy (Kumar, 2000). Most 
commercial chitosans have a degree of deacetylation that is greater than 70% and a 
molecular weight ranging between 100,000 and 1.2 million Da (Li et al., 1997). Chitosans are 
of commercial interest due to their high percentage of nitrogen compared to synthetically 
substituted cellulose, rendering them useful for metal chelation and polyoxysalt and film 
formulations. Chitosan is polycationic at pH< 6 and it readily interacts with negatively 
charged molecules, such as proteins, anionic polysaccharides (e.g. , alginate and cargeenan), 
fatty acids, bile acids and phospholipids (Muzzarelli, 1996). Nonetheless, chitosan may also 
selectively chelate metal ions such as iron, copper, cadmium and magnesium.  
Wound healing is defined as a tissue restoration and reparative process that is typically 
comprised of a continuous sequence of inflammation and repair, in which epithelial, 
endothelial and inflammatory cells, platelets and fibroblasts interact to resume their normal 
functions. The wound healing process is regulated by cytokines and growth factors and 
consists of four phases: the process is initialized by inflammation, followed by granulation, 
matrix remodeling and re-epithelialization. Research is currently being conducted to 
discover ways for humans to heal via regeneration and the use of a variety of dressing 
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materials to facilitate proper wound management. Significant advancement in wound care 
was pioneered by moist wound healing theory in the 1960’s, which determined that 
occluded wounds healed faster than dry wounds and a moist wound healing environment 
increased the healing rates (Winter, 1962). 
 
 
Fig. 1. Chemical structures of chitin and chitosan. 
Chitosan has been widely used as a biomedical application due to its excellent 
biocompatibility (Keong & Halim 2009; Lim et al., 2010). Chitosan is a benefit to wound 
healing because it stimulates hemostasis and accelerates tissue regeneration (Hoekstra et al., 
1998). For a material to be used for biomedical research, it is more preferable a natural 
product  because these materials are more biocompatible than synthetic materials. Chitosan 
is metabolized by certain human enzymes, such as lysozyme. Thus, chitosan is 
biodegradable. Chitosan is an attractive material for a tissue engineering scaffold because it 
has structural similarities to glycosaminoglycans and is hydrophilic. Chitosan’s monomeric 
unit, N-acetylglucosamine, occurs in hyaluronic acid, an extracellular macromolecule that is 
important in wound repair. An effective approach for developing a clinically applicable 
chitosan is to modify the surface of the material to provide excellent biofunctionality and 
bulk properties. Surface modification techniques to blend various compound derivatives 
include coating, oxidation by low-temperature plasma and surfactant addition in order to 
blend with various derivatives. Furthermore, chitosan can be fabricated into a stable, porous 
bioscaffold via surface modification and lyophilization. However, blending with various 
additives may affect its biocompatibility. Therefore, evaluation of the biocompatibility of 
various biomedical-grade chitosan derivatives is necessary to engineer material that is of 
high quality and biocompatible for human wound management. 
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2. Chitosan and its derivatives 
The practical use of chitosan is restricted to its unmodified forms in wound management, 
mainly due to its insolubility in water, high viscosity and its tendency to coagulate with 
proteins at high pH. Recently, modification of chitosan has been found to improve 
solubility. The introduction of various chemical side chains provides desired properties and 
expands the potential applications for chitosan use. Alteration of the molecular weight 
forms water-soluble chitosans, such as the randomly 50% deacetylated and partially 
depolymerized chitosans. Chitosan purification from proteins, carotenoids and inorganics 
produces a product of technical, food, pharmaceutical and medical grade, which is 
approved for use in many countries. Alkali treatment of chitin removes protein and 
deacetylates the chitin. Some soluble glycans can also be removed depending on the alkali 
concentration (Madhavan, 1992). In particular, processing of crustacean shells involves the 
removal of proteins and the dissolution of calcium carbonate, which is abundant in crab 
shells. Deacetylation of chitosan in 40% sodium hydroxide at 120 oC for 3 hours is 
approximately 70% efficient. However, it is necessary to perform additional modification on 
these polymers to improve the chemical properties. 
Chitosan has one amino group and two hydroxyl groups in the repeating hexosamide 
residue. Chemical modification of these groups during a regeneration reaction creates 
various novel biofunctional macromolecular products that have an original or novel 
organization. Hence, the bioactivities of chitosan unmodified and in formulation with 
various drugs may have dual therapeutic effects. In its crystalline form, chitosan is only 
soluble in an acidic aqueous medium (pH < 6), such as acetic acid, formic acid and lactic 
acid, in which solubility is conferred by the protonated free amino groups on the 
glucosamine. Another limitation of sustained release chitosan systems is that they rapidly 
adsorb water and have a high swelling degree in aqueous environments, which causes rapid 
drug release to occur. Therefore, several chemically modified chitosan derivatives have been 
synthesized and examined to improve solubility and versatility (Jayakumar et al., 2005; 
Prabaharan & Mano, 2007). Chemically modified chitosan structures may result in improved 
solubility in general organic solvents (Qurashi et al., 1992). For example, phosphorylated 
chitosan is a water-soluble derivative of chitosan, which is potentially important for drug 
delivery systems. Non-covalent cross-linking is a useful method to prepare hydrogels from 
polymers for drug delivery. These gels are likely biocompatible due to the absence of 
organic solvents. The use of organic solvents may potentially lower drug absorption.    
Chitosan derivatives are easily obtained under mild conditions and can be rendered as 
substituted glucans. The nitrogen content of chitin varies from 5% to 8% depending on the 
extent of deacetylation, whereas the majority of nitrogen in chitosan is in the form of 
aliphatic amino groups. Hence, chitosan undergoes reactions that are typical of amines, such 
as N-acylation and the Schiff reaction. N-acylation with acid anhydrides or acyl halides 
introduces amino groups on nitrogens in chitosan. Acetic anhydride fully acetylates chitins. 
Linear aliphatic N-acyl groups above propionyl allow prompt acetylation of hydroxyl 
groups. At room temperature, chitosan is able to form aldimines and ketimines with 
aldehydes and ketones, respectively. A reaction with ketoacids, followed by a reaction with 
sodium borohydride produces glucans that have proteic and non-proteic amino groups. For 
example, non-proteic amino acid glucans derived from chitosan are the N-carboxybenzyl 
chitosans obtained from o- and p-phthalaldehydic acids (Madhavan, 1992). N-carboxymethyl 
chitosan is derived from glyocylic acid. Chitosan and simple aldehydes produce N-alkyl 
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chitosan upon hydrogenation, where the presence of a bulky substituent can deteriorate the 
hydrogen bonds of chitosan. This compound swells in water in spite of the presence of 
hydrophobic alkyl chains (Muzarelli, 1973).  
The Schiff reaction between chitosan and aldehydes or ketones yields the corresponding 
aldimines and ketimines, which can be converted to N-alkyl derivatives upon 
hydrogenation with borohydride. The film-forming ability of N-carboxymethyl chitosan 
imparts a pleasant feeling of smoothness to the skin and protects from adverse 
environmental conditions and consequences of detergent use. In addition, N-carboxymethyl 
chitosan is superior to hyaluronic acid in terms of its hydrating effects. Chitosan with 
several molecular designs, is presented when an alkyl or acyl chain is chemically 
introduced. For example, the introduction of an alkyl chain onto water-soluble modified 
chitosan (N-methylene phosphonic chitosan) introduces both hydrophobic and hydrophilic 
side chains. The presence of alkyl groups in N-lauryl-N-methylene phosphonic chitosan 
weakens the hydrogen bond and provides good solubility in organic solvents (Ramos et al., 
2003). In addition, chitosan that is bound with sialic acid using p-formylphenyl-a-sialoside 
by reductive N-alkylation is a potent inhibitor of the influenza virus and is used as a 
blocking agent for acute rejection (Gamian et al., 1991).  
Polyethylene glycol (PEG) is a water-soluble polymer that exhibits useful properties, such as 
protein resistance, low toxicity and immunogenicity. PEG is mixed with chitosan to produce 
the chitosan derivatives with improved biocompatibility. Chitosan-PEG enhances the 
protein adsorption, cell adhesion, growth and proliferation (Zhang et al., 2002). N-acylation 
of chitosan with various fatty acid (C6-C16)) chlorides may increase its hydrophobic character 
and make important structural changes and can be used as a matrix for drug delivery (Tien 
et al., 2003). Furthermore, chitosan may also be grafted with biomolecules similar to the 
chitosan derivatives. The conjugation of lipid groups to the chitosan molecule creates an 
amphiphilic self-aggregate molecule that is useful for drug delivery systems. One example 
of this is palmitoyl glycol chitosan (GCP), which is prepared by reacting glycol chitosan and 
sodium bicarbonate with palmitic acid N-hydroxysuccinimide in an ethanol solution 
(Uchegbu et al., 2001). In a different approach, the reaction of the amino group on chitosan 
and the carboxylic acid group on amino acids with glutaraldehyde may attach various 
amino acids (lysine, arginine, phenylalanine and aspartic acid) to a chitosan molecule. These 
amino acid-functionalized chitosan moieties are entrapped on poly L-lactide (PLA) surfaces 
(Figure 2). 
 
 
Fig. 2. Entrapment of functionalized chitosan on a PLA. In this process, the solvent swells 
the surface of the PLA to allow penetration of the amino acid-chitosan derivatives. These 
adhere upon addition of a non-solvent chitosan solution (Chung et al., 2002). 
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3. Chitosan in wound management 
A wound is defined as the disruption of the anatomic structure and function of a body part. 
This may be the result of a simple cut, burns and any other injuries. Wounds are generally 
classified as wounds without tissue loss (e.g., surgical incision) or wounds with tissue loss, 
such as burn wounds, wounds due to trauma, abrasions or secondary events to chronic 
ailments (e.g., venous stasis, diabetic ulcers and iatrogenic wounds, such as skin graft donor 
sites and dermabrasions). In contrast, wound healing is a process of restoration by which 
tissue repair takes place and usually is comprised of a continuous sequence of inflammation 
and tissue repair during which epithelial, endothelial, inflammatory cells, platelets and 
fibroblasts briefly interact to restore normal function. The ordered sequence of healing 
events is accomplished and regulated by cytokines and growth factors. Soon after the 
elimination of macrophages, which appear during the inflammatory phase, wound healing 
is impeded and the tensile strength of the scar is diminished. 
The use of chitosan has advantages due to the biocompatibility and biodegradability of the 
molecules, which does not harm the environment. When chitosan is applied to the body, 
besides being biocompatible, it is then slowly biodegraded by lysozymes, chitinase and 
chitosanase to harmless oligomers and monomers (amino sugars), which are completely 
absorbed by the body. Chitosan embodies analgesic, bacteriostatic and fungistatic 
properties, which are particularly useful for wound treatment. Additionally, chitosan 
modulates macrophage function and the secretion of numerous enzymes (e.g., collagenase) 
and cytokines (e.g., interleukins and tumor necrosis factor) during the wound healing 
process (Majeti & Ravi, 2000). The degradation of chitosan into monomers and oligomers at 
a wound site significantly accelerates the wound healing process (Minagawa et al., 2007). In 
addition, clinical studies have shown an absence of scar formation at the wound site in the 
presence of chitosan (Okamoto et al., 1993; Okamoto et al., 1995). Chitosan structurally 
resembles glycosaminoglycans (GAG), which have long-chain, unbranched, repeating 
disaccharide units and are important for maintaining cell morphology, differentiation and 
function (Nishikawa et al., 2000). GAG and proteoglycans are widely distributed throughout 
the human body and may bind and modulate numerous cytokines and growth factors, 
including heparin and heparan sulfate. Hence, the cell-binding and cell-activating properties 
of chitosan are crucial for wound healing.  
Various chitosan derivatives have been produced for wound management, particularly to 
enhance wound healing. For example, oligo-chitosan (O-C) and N, O- carboxymethyl-
chitosan (NO-CMC) derivatives have been fabricated into films for wound dressing (Lim et 
al., 2007). N-carboxybutyl chitosan has also been used in patients undergoing plastic surgery 
to promote tissue regeneration. The use of N-carboxybutyl chitosan improves cutaneous 
tissue regeneration with good histoarchitecture and vascularization at the wound site 
(Biagini et al., 1991). Additionally, 5-methylpyrrolidinone chitosan is compatible with other 
polymer solutions (e.g., gelatin, polyvinyl alcohol, polyvinyl pyrrolidone, and hyaluronic 
acid), which are beneficial for the treatment of wounded meniscal tissues, decubitus ulcers, 
depression of capsule formation around prostheses, scar formation and retraction during 
wound healing (Muzzarelli, 1995). 
3.1 Analgesic, antimicrobial and anti-inflammatory effects of chitosan in wound 
healing 
Chitosan treatment reduces inflammatory pain due to intraperitoneal administration of 
acetic acid in a dose-dependent manner. Studies suggest that chitosan has potent analgesic 
actions. Bradykinin is one of the main substances related to pain. Okamoto et al. (2002) 
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reported that the bradykinin concentration during administration of a chitosan-acid acetic 
solution in the peritoneal lavage fluid was lower than during the administration of a 0.5% 
acetic acid solution, suggesting that chitosan has analgesic effects. Open wounds are often 
associated with severe pain in patients. Chitosan that is formulated for wound management 
may induce analgesia by providing a cool, pleasant and soothing effect when applied to an 
open wound. Excellent pain relief is conferred by chitosan when it is applied as a topical 
agent to open wounds, such as burns, skin abrasions, skin ulcers and skin grafted areas 
(Ohshima et al., 1987).  
Chitosan-dependent antimicrobial activity has been observed against various 
microorganisms, such as fungi, algae and bacteria. These antimicrobial effects are controlled 
by intrinsic factors, including the type of chitosan, the degree of chitosan polymerization, 
the host, the natural nutrient constituency, the chemical or nutrient composition of the 
substrates and the environmental conditions (e.g., substrate water activity or moisture or 
both). The antimicrobial activity of chitosan differs mainly in live host plants. For example, 
the fungicidal effects of N-carboxymethyl chitosan (NCMC) are different in vegetable and 
graminea hosts. The antimicrobial activity is more immediate on fungi and algae than on 
bacteria (Savard et al., 2002). Furthermore, in the presence of more than 0.025% chitosan, the 
growth of Excherichia coli, Fusarium, Alternaria and Helminthosporium is inhibited (Hirano, 
1995). The cationic amino groups of chitosan bind to anionic groups in these 
microorganisms, resulting in growth inhibition. During the infectious period of a burn 
wound, bacterial infection may delay the healing and probably cause serious complications, 
such as sepsis. Chitosan that is incorporated with minocycline hydrochloride (CH-MH) was 
therefore developed to achieve both wound healing enhancement and antibacterial effects 
(Aoyagi et al., 2007).  
Chitosan has anti-inflammatory effects that are beneficial for the treatment of prolonged 
inflammation at the wound site. Water-soluble chitosan (WSC) significantly suppresses the 
secretion and expression of proinflammatory cytokines (e.g., tumor necrosis factor-┙ and 
interleukin-6) and inducible nitric oxide synthase (iNOS) in astrocytes, the predominant 
neuroglial cells in the central nervous system, and is actively involved in cytokine-mediated 
inflammatory events (Kim et al., 2002). Moreover, N-acetylglucosamine is an anti-
inflammatory drug and is synthesized in the human body from glucose. It is incorporated 
into glycosaminoglycans and glycoproteins. Chito-oligosaccharides (COS), which have a 
molecular weight of 5 kDa, are better anti-inflammatory agents than indomethacin, a non-
steroidal anti-inflammatory drug (Spindola et al., 2009). Chitosan exerts anti-inflammatory 
effects by inhibiting prostaglandin E2 (PGE2) and cyclooxygenase-2 (COX-2) protein 
expression and attenuating the pro-inflammatory cytokines (e.g., tumor necrosis factor-┙ 
and interleukin-1┚). However, chitosan treatment increases the expression of the anti-
inflammatory cytokine, interleukin-10 (Chou et al., 2003). 
3.2 Chitosan-based wound dressings 
Wound dressings are generally classified by their mechanism of action. They are termed 
passive products, interactive products and bioactive products. Wound dressings before the 
1960s were considered passive products minimally affected the wound healing process. 
Gauze and tulle dressings accounted for the largest market segment. Polymeric films, which 
are mostly transparent, permeable to water vapor and oxygen but impermeable to bacteria, 
are commonly recognized as interactive products. Bioactive dressings are important for the 
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delivery of substances for wound healing, for which the delivery of bioactive compounds or 
dressings is constructed from material having endogenous activity, such as proteoglycans, 
collagen, non-collagenous proteins, alginates or chitosan. The pioneering research by Winter 
(1962) initiated the concept of a wound dressing that establishes an optimal environment for 
wound healing. Therefore, the development of wound dressings from traditional passive 
materials was replaced by active dressings that create and maintain a moist, healing 
environment. An ideal wound dressing must be biocompatible, able to protect the wound 
from bacterial infection and should provide a moist, healing environment (Purna & Babu, 
2000). 
Some wound dressings are prepared from aqueous solution of 5-methylpyrrolidinone 
chitosan, which is dialyzed and laminated between stainless steel plates and freeze-dried to 
yield fleeces. The material can be fabricated into many forms, such as  nonwoven fabrics, 
filaments and so forth. 5-methylpyrrolidinone forms oligomers when applied to a wound 
site due to lysozyme-derpendent degradation. Flexible, thin, transparent novel chitosan-
alginate polyelectrolyte complex (PEC) membranes accelerate the healing of incision 
wounds in a rat model in comparison to a conventional gauze dressing. The closure rate and 
appearance of wounds treated with a PEC membrane were comparable with wounds 
treated with Opsite (Wang et al., 2002). In addition, the chitosan-based Hyphecan cap is 
useful in the management of deepithelializing fingertip injuries, achieving shorter healing 
time (Halim et al., 1998). A chitosan bilayer derived from sulfadiazine has excellent oxygen 
permeability, water vapor transmission rate and water-uptake capability, which benefits the 
wound dressing (Mi et al., 2001). Chitosan complexed with gelatin has been useful as a 
surgical dressing. It is prepared by dissolving the chitosan in an acidic solution before 
addition to gelatin at a ratio of 3:1 chitosan and gelatin (Sparkes & Murray, 1986). The 
stiffness of the resulting chitosan-gelatin dressing is reduced by the addition of plasticizers 
such as glycerol and sorbitol. Additionally, chitosan gels may be used in surgery and 
dentistry as a biological adhesive to seal wounds and to improve wound healing. 
3.3 Chitosan as a tissue engineering scaffold for artificial skin 
Individuals who suffer from extensive skin loss are in danger of succumbing to either 
massive infection or severe fluid loss. Patients often cope with problems of rehabilitation 
arising from deep, disfiguring scars and crippling contractures. Tissue repair requires a 
complex biological process, where inward cell migration and the proliferation of various 
types of neighboring cells concertedly restores tissue function.  
Tissue engineering is a recent, advanced technology to develop living tissue substitutes and 
replace diseased or damaged tissues and organs in the human body. Tissue engineering 
applies the development of polymeric scaffolds, that, among other characteristics, are 
biodegradable and biocompatible. These scaffolds may be used simultaneously as a carrier 
matrix for bioactive agents and as a support for primary undifferentiated cells in vitro. The 
three-dimensional (3D) framework of a scaffold must be able to promote adherence, 
proliferation and differentiation of cells, which ultimately are guided to form the desired 
tissues. Biological scaffolds are mostly biodegradable and biocompatible, and, with the 
appropriate growth factors, induce cell growth. In addition, a biological scaffold must also 
fill space with optimal mechanical strength and control the release of bioactive molecules. 
Current tissue engineered systems cover every tissue and organ, with skin and cartilage 
constructs for repair of skin loss and joints already clinically performed (Pomahac et al., 
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1998; Kuo et al., 2006). Acute, chronic, and more extensive wounds or skin loss would be 
inevitable unless some skin substitutes are applied. The primary role of skin substitutes is to 
promote wound healing by stimulating the host to produce various cytokines, which may 
promote the formation of granulation tissue during the wound healing process. Cultured 
skin from human cells is extremely thin and needs mechanical support from biopolymer 
complexes, such as collagen, fibrin or chitosan. Hence, skin tissue engineering produces a 
construct that offers the complete regeneration of functional skin. It restores normal 
functions, such as barrier formation, pigmentory defence against UV irradiation, 
thermoregulation and mechanical and aesthetic functions. During the past couple decades, 
xenografts, allografts and autografts have been used as skin substitutes for wound healing. 
However, skin substitutes occasionally do not provide skin recovery and cause antigenicity 
at the donor site. Therefore, these are not widely used. 
In general, the substrate material upon which the cells are cultured enhances cellular 
organization in 3D and provides the initial mechanical integrity for the cell-polymer 
construct. Chitosan-based scaffolds are of current interest for tissue engineering because 
these natural products are mostly biocompatible and biodegradable. Moreover, the natural 
components of living structures have biological and chemical similarities to tissues, in which 
formation of the native extracellular matrix (ECM) is crucial. One of chitosan’s most 
promising features is its excellent ability to form porous structures for use in tissue 
transplantation or as template for tissue regeneration. Chitosan scaffolds are commonly 
porous-structured by freezing and lyophilizing a chitosan solution (Figure 3). Alternatively, 
the creation of porous chitosan scaffolds may also be achieved through an internal bubbling 
process (IBP). In this process, calcium carbonate (CaCO3) is added to a chitosan solution to 
generate a chitosan-CaCO3 gels in a specific shape of a mold (Chow & Khor, 2000). The 
interconnected porous structure is crucial, and numerous cultured cells can be seeded onto 
it. Cells proliferate and migrate within the scaffold and ultimately form a tissue or organ. 
 
 
Fig. 3. A chitosan porous skin regenerating template (CPSRT) produced by lyophilization 
process in a freeze dryer for 24 hours. 
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Because chitosan is positively charged, the negatively charged cell surface binds 
electrostatistically with chitosan and grows in the presence of a medium in vitro (Figure 4). 
For example, a CPSRT that is seeded with skin cells, such as keratinocytes or fibroblasts, 
may form a skin sheet-like tissue. However, regulation of porosity and pore morphology of 
a chitosan-based scaffold is particularly important to control angiogenesis, the cellular 
colonization rate and organization within an engineered tissue in vitro. The mechanical 
properties of chitosan scaffolds formed by the lyophilization technique are primarily 
dependent on pore size and pore orientation. Tensile testing of hydrated samples shows that 
porous membranes can greatly reduce elastic moduli compared to non-porous chitosan 
membranes. Their mean pore size is typically controlled by varying the temperature, 
whereas the pore orientation can be directed by controlling the geometry of the temperature 
gradients during freezing and thermal gradients. The freezing and lyophilizing process 
generates an open microstructure with a high degree of interconnectivity within the inner 
layer compared with that of the surface layer. In addition, chitosan-gelatin scaffolds have 
also been used to construct an artificial skin bilayer in vitro that consists of co-cultured 
keratinocytes and fibroblasts (Mao et al., 2003). 
 
      
                           (a)                                                                             (b) 
Fig. 4. CPSRT viewed using a scanning electron microscopy (SEM). (a) Porous structures of a 
CPSRT without cultured cells. (b) Proliferating cells in the CPSRT. 
3.4 Sterilization issues for chitosan as wound dressing 
Chitosan products intended for parenteral administration or in contact with bodily fluids 
(e.g., wounds) must be sterilized before use. Sterilization using dry heat, saturated steam 
autoclaving, ethylene oxide (EO) and gamma irradiation are among the current methods 
used for most pharmaceutical and medical products. It is often assumed that the existing 
sterilization technologies are adequate for chitosan material. A focus on the efficacy of the 
strerilization process in terms of killing microorganisms, the nature of the residuals formed 
and the properties of the chitosan must not be ignored. Deleterious effects of a sterilization 
method on the chitosan material should be minimal. 
Before a sterilization method for chitosan products is approved, the effects of sterilization on 
the properties and performance of the biopolymer must be evaluated and documented. 
Sterilization methods either chemically or physically result in lethal alteration of the 
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structure or function of the biomolecule microorganisms. Therefore, various forms of 
sterilization may also affect the chitosan biopolymers by similar mechanisms, resulting in 
hydrolysis, oxidation, chain scission, depolymerization or cross-linking of the polymer. For 
example, saturated steam autoclaving may not be suitable to sterilize chitosan that is 
complexed with proteins, growth factors or enzymes. This is because the high temperature 
may completely denature the biomolecules and result in poor biopolymer performance. In 
addition, heat may alter the physical properties of chitosan, affecting its aqueous solubility, 
rheology and appearance. Exposure to dry heat resulted in lower chitosan aqueous 
solubility and insolubility in some acidic aqueous media (Lim et al., 1999). This may be 
related to the interchain crosslink formation that involves the amino (NH2) group in 
chitosan, causing a reduction in the tensile strength and strain at the break point. 
Gamma irradiation causes main chain scission events in chitosan (Lim et al., 1998). 
Irradiation with 2.5 Mrad in air improved the tensile strength of the chitosan film, which is 
probably due to changes in chain interaction and rearrangement. Additionally, gamma 
irradiation may have depolymerized chitosan at a radiation dose of 10 kGy (Yang et al., 
2007). However, applying anoxic conditions during irradiation did not affect film properties, 
in part due to the pre-irradiation application of negative pressure that may minimally affect 
the structure of the chitosan film. Hence, gamma irradiation at 2.5 Mrad under anoxic 
conditions may provide suitable sterilization for chitosan products. In addition, sterilization 
using saturated steam autoclaving is recommended for chitosan products becasue it retains 
the tensile strength of the chitosan film (Rao & Sharma, 1997). Nonetheless, saturated steam 
autoclaving causes darkening of chitosan to a yellow color, which may result from the 
Maillard reaction between NH2 and OH groups (Yang et al., 2007). However, sterilization of 
chitosan derivatives and porous-structured chitosan scaffolds using EO was also reported to 
retain the biocompatibility of the porous chitosan (Lim et al., 2007; Lim et al., 2010). 
Chitosan that is sterilized using EO must be quarantined and saline-irrigated prior to use to 
remove EO residues. Chitosan sterilized by EO that was quarantined under aeration for 10 
days was void of EO residues. Additionally, the chemical properties and structure of 
chitosan were not affected after EO, as determined by Fourier transform infrared 
spectroscopy (FTIR) (Yang et al., 2007). Hence, the sterilization method used for chitosan 
derivatives may depend greatly upon the type of application. 
4. In vitro biocompatibility evaluations of chitosan as a wound dressing 
The application of in vitro model systems to evaluate toxicity significantly enhances our 
understanding of the mechanisms of drug- and chemical-induced toxicity. Biocompatibility 
of a biomaterial refers to the extent to which the material does not have toxic or injurious 
effects on biological systems. This means that patient’s tissue, that comes into contact with 
the material does not suffer from any toxic, irritating, inflammatory and genotoxic effects. 
The United States Food and Drug Administration (FDA), the International Organization for 
Standardization (ISO) and the Japanese Ministry of Health and Welfare (JMHW) require 
that manufacturers conduct adequate safety testing of their finished devices through pre-
clinical and clinical phases as part of the regulatory clearance process. In vitro models for 
testing the biocompatibility of chitosan and chitosan derivatives are useful to evaluate the 
toxicity, particularly from the leachability of chitosan as residual monomers or oligomers. 
Moreover, current in vitro toxicity models are preferred to in vivo models as the preliminary 
method to evaluate newly developed dressing materials. These models examine materials 
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outside the body, and data are more reproducible. The use of these methods eliminates 
concerns about animal ethical issues and subsequently reduces the number of animals used 
in the in vivo biocompatibility tests.  Because thousands of drugs and chemical compounds 
are synthesized every year, the cost of animal testing, which may be expensive, needs to be 
reduced. The use of animals to evaluate materials may also be very time consuming. 
Moreover, in vivo models are complicated due to the presence of structural and functional 
heterogeneity, and these models do not clearly define or evaluate drug mechanism. 
Analysis of the effects of newly developed chitosan in cell culture systems is useful as a 
screening tool for their potential activity in vivo as wound healing agents. However, it is 
important to select appropriate cell lines for in vitro biocompatibility screening. If chitosan 
and its derivatives were meant to be used to treat bone injuries, osteoblast or chondrocyte 
cell cultures would be appropriate for the experiment. In addition, fibroblast and 
keratinocyte cell culture systems are more reasonable for biocompatibility in vitro 
experiments for chitosan in wound management. Various in vitro cell culture systems have 
been used to investigate and evaluate cellular processes, such as fibroblast and keratinocyte 
proliferation and cell migration toward growth factors present in a wound (Kawada et al., 
1997). However, normal cell or non-transformed cell culture models are of particular interest 
for in vitro biocompatibility studies of cutaneous toxicity. Studies of new wound dressings, 
new drugs, cosmetic products and other chemicals require phenotypically normal cell 
systems. In addition, correlation of in vitro biocompatibility testing with in vivo irritation 
potential has been used with normal keratinocyte cultures rather than transformed cell lines 
(Korting et al., 1994). These in vitro models are simple methods to assess material 
biocompatibility and the ability of chemicals and biomaterials to promote cell proliferation 
during wound repair. Model compounds, which are known to be toxic (positive control) or 
non-toxic (negative controls), must be included to determine the validity of the in vitro 
system. The effects of unknown agents are compared to the effects of the controls. For 
example, organotin-polyvinylchloride (PVC) and high density polyethylene (HDPE) are 
used as positive and negative controls, respectively, in a direct-contact in vitro 
biocompatibility assay for chitosan wound dressing materials.  
Numerous biocompatibility in vitro tests must be performed prior to the approval of 
chitosan products for human use. Otherwise, side effects and tissue toxicity will cause long-
term effects, such as alteration of the immune system and development of malignancies, due 
to genetic damage induced by drug treatment. Optimal in vitro biocompatibility must mimic 
the biological response to materials when they are in contact with tissue. Therefore, in vitro 
biocompatibility testing of newly developed chitosan should measure cellular and 
molecular responses in cultured cells.  
4.1 Cellular assessment: cytotoxicity in vitro 
In vitro cytotoxicity is considered the most preliminary procedure in the biocompatibility in 
vitro assay. Cultured cells may undergo necrosis, a disruption of membrane integrity, or 
apoptosis (molecularly-controlled cell death) following treatment with cytotoxic 
compounds.  
Cytotoxicity assays are commonly used to measure the response of cells to toxic substances. 
These measurements are of either an end-stage event (e.g., permeability of cytoplasmic 
membranes of dead and dying cells) or some metabolic parameter (e.g., cell division and 
enzymatic reaction). For example, trypan blue and propidium iodide dye exclusion assays 
are relatively simple assessment of cell membrane integrity, an end-stage event. These dyes 
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are normally excluded from the interior of healthy cells. Cell membranes become 
compromised, when exposed to cytotoxic compounds, allowing trypan blue or propidium 
iodide dyes to cross the membrane and stain intracellular components. The staining is 
visible under light microscopy. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) and 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) are substrates that are reduced enzymatically only in 
viable cells, to form formazan crystals, which are either dissolved in organic solvent (MTT 
assay), or  water (MTS assay). The formation of formazan results in a purple color that is 
used as an indicator of viable cells. The absorbance of the colored solution is measured (e.g., 
500 to 600 nm) using a spectrophotometer to generate quantitative data. MTT is a proven, 
reliable and cost-effective method to measure cell viability in vitro (Lim et al., 2007; Keong & 
Halim, 2009; Lim et al., 2010). In addition, lactate dehydrogenase (LDH) is a stable 
cytoplasmic enzyme present in most cell types and is instantly released into cell culture 
medium upon rupture of the cell membrane. The LDH concentration in the medium is 
proportional to the number of dead or damaged cells. Measurement of LDH is a useful cell-
mediated and drug-mediated cytotoxicity assay in vitro.   
4.2 Genetic assessment: genotoxicity in vitro 
Even though biocompatibility is typically measured by cytotoxicity, there is a growing 
concern that newly developed chitosan wound dressings may exert genotoxic effects. 
Hence, the safety assessment of a newly developed chitosan intended for body contact or 
permanent implantation would be incomplete without genotoxicity assays. When 
substances impose a genotoxic effect by damaging and mutating the deoxyribonucleic acid 
(DNA) of the cells, the growth of viable cells is abnormal or fully retarded. 
The Ames test and the in vitro micronucleus assay are among the oldest genotoxicity assays 
and are commonly used. The Ames test, a salmonella point mutation assay that assesses five 
strains of bacterium Salmonella typhimurium, is used to determine the mutagenic potential of 
chemical compounds. The basis of the Ames test is that the salmonella bacteria cannot 
reproduce in growth medium unless bacteria undergo mutation. The Ames test is a high 
throughput genotoxicity screen that requires a small amount of test substance 
(approximately 2 mg). This test is relatively sensitive and accurate and is an immediate 
indicator of chemical mutagenic activity. The in vitro micronucleus assay, on the other hand, 
tests the effects of a compound on the induction of chromosomal breakage or clastogenesis. 
This assay evaluates the induction of micronuclei, which is the product of chromosomal 
breakage using Chinese hamster ovary (CHO) cells. Micronuclei occur in the cytoplasm 
following cell division. Therefore, the cellular replication kinetics and the percentage of 
binucleated cells with micronuclei are measured. This high throughput assay requires 
relatively little compound (3 mg). These early genotoxic tests may predict the toxicity 
potential and identify compounds for further tests. 
The single-cell gel electrophoresis (SCGE) or Comet assay also has been a useful approach 
for assessing DNA damage. This technique is relatively more sensitive and is less expensive 
than other genotoxicity assays, that measure low levels of DNA damage. In addition, it 
requires few eukaryotic cells and test substance. The term “comet“ describes the migration 
pattern of fragmented or unwound DNA caused by genotoxicity (Figure 5). The first comet 
assay was originally developed two decades ago using neutral conditions (Ostling & 
Johanson, 1984). In this method, cells are embedded in agarose and lysed by detergents. The 
liberated DNA is electrophoresed under neutral conditions. However, the measurement of 
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the breaking  potency (e.g., comet tail length and comet tail intensity) is limited to DNA with 
double-strand breaks (DSB). Therefore, a more sensitive comet assay has been introduced, 
which uses alkaline electrophoresis conditions (pH > 13) to detect DNA damage in single 
cells (Singh et al., 1988). This new method not only detects DNA with DSB, but also detects 
single-strand break (SSB) and alkali-labile sites (ALS) which may result from genotoxic 
agents. Furthermore, the production of DNA strand breaks correlates with the mutagenic 
and carcinogenic properties of environmental pollutants (Mitchelmore & Chipman, 1998). 
 
 
Fig. 5. Cultured human skin keratinocytes treated with a newly developed CPSRT that 
imposes a genotoxic effect, leading to DNA breakage. Subsequently, a comet-like shape is 
produced after electrophoressis at a constant voltage.  
4.3 Human skin pro-inflammatory cytokine assessment: skin irritation in vitro 
It is necessary not only to assess the cytotoxicity and genotoxicity of these materials, but also 
to determine the inflammatory potential in vitro. Despite being inert and non-toxic, newly 
developed chitosan wound dressings trigger adverse foreign body reactions, such as 
inflammation. Various cells in the dermis and epidermis are involved in these responses and 
they secrete various cytokines, particularly pro-inflammatory cytokines that cause skin 
irritation in vitro. Cytokines are low molecular weight glycoproteins that are produced by 
immune and non-immune cells. They are pleiotropic and interact with various receptors 
expressed on the surface of target cells. The binding of cytokines to cell surface receptors 
triggers intracellular signaling, protein synthesis and the production of other cytokines. The 
induction of other cytokines is regulated by autocrine, juxtacrine or paracrine pathways in 
response to micro-environmental stimuli. Cytokines mediate the interaction between 
various cells, and cytokine dysregulation indicates disease pathogenesis (Lazutka, 1996). 
Pro-inflammatory cytokines are detected at low levels in body fluids and in tissues under 
normal circumstances. Elevated expression may indicate activation of cytokine pathways 
associated with inflammation or disease progression. 
The skin is the primary target tissue for exogenous noxes, which protect against harmful 
environmental hazards, UV-radiation and endogenous water loss. The skin epidermis 
consists mainly of keratinocytes, in which the cornified keratinoyctes in the outermost layer 
is an effective barrier against a vast number of substances. Upon stimulation, keratinocytes 
conduct immune  surveillance of the epidermis and stimulate inflammatory responses 
(Steinoff et al., 2001). Harvell et al. (1995) defined skin irritation as a local, non-immunogenic 
inflammatory reaction that appears shortly after stimulation and usually disappears after a 
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few days. Skin irritation is one of the most common adverse responses to cutaneous 
inflammation. The presence of erythema, oedema, dryness of the skin, fissures, 
desquamation, itching and pain are attributed to both irritant contact dermatitis and allergic 
contact dermatitis. Testing for skin irritation in animals can potentially cause them pain and 
discomfort. The results are not always reflective of effects in humans (Nixon et al., 1975; 
York et al., 1996). Hence, several alternative in vitro tests were developed, of which the in 
vitro reconstructed organotypic skin equivalents is the most favored, because of its 
resemblance to the structure of human skin. There are two different kinds of reconstituted 
skin equivalents available: 1) epidermal equivalents that consist of multilayered, 
differentiated human keratinocytes grown on a synthetic matrix, and 2) full skin equivalents 
consisting of multilayered, differentiated human keratinocytes grown on fibroblasts 
containing collagen matrices. Currently, various companies provide reconstituted human 
epidermal in vitro skin equivalents, such as EpiDerm (MatTek, Ashland, MA, USA), Episkin 
(Episkin, Chaponost, France), Apligraf (Organogenesis Inc., MA, USA) and Skinethic 
(Skinethic, Nice, France). In addition, because keratinocytes initiate and regulate skin 
irritation (Coquette et al., 2000), keratinocyte cultures may also serve as indicators for skin 
irritation in vitro. 
Keratinocytes, the principle epidermal cell, is also a major contributor to epidermal cytokine 
production, a fact that is not well recognized by the immunology community (Tizard, 2000). 
Nevertheless, numerous cytokines are produced by keratinocytes (e.g., Interleukin-1, -6, -7, -
8, -10, -12, -15, -18 and -20 and tumor necrosis factor-┙), either constitutively or upon 
induction by stimulants (Grone, 2002). These cytokines trigger multiple biological events, 
such as the migration of inflammatory cells, systemic effects on the immune system, 
keratinocyte proliferation and differentiation and the production of other cytokines. Lim et 
al. (2010) reported that non-biocompatible chitosan wound dressings increase the 
production of tumor necrosis factor-┙ and interleukin-8 in an experiment using keratinocyte 
cultures in an in vitro assay. Regardless of the chemical class or mechanism of drug action, 
the onset of skin irritation by chemicals and newly developed chitosan derivative wound 
dressings is in accordance with the general principles of toxicology. These biologic effects 
depend on various factors, such as the concentration of the test substance, the duration and 
frequency of exposure, the rate of penetration and the intrinsic toxic potential of the 
substance.  
5. Conclusion  
Chitosan and chitosan-based derivatives have various medical applications. It is well-
known that chitosan possesses medicinal properties that accelerate wound healing and 
tissue regeneration. Chitosan is a natural product. It is biocompatible and biodegradable, 
enabling it to be used for wound dressing material. However, the practical use of chitosan is 
restricted to the unmodified forms, as these are water-insoluble and have high viscosity and 
the tendency to coagulate with proteins at high pH. Thus, chemical modification of chitosan 
may ultimately enhance its solubility and potential use for wound dressings. Chitosan has 
analgesic, antimicrobial and anti-inflammatory effects, which are beneficial for wound 
treatment. Chitosan is widely applied for the development of various chitosan-based wound 
dressings and biological scaffolds for tissue engineering. Nevertheless, each chitosan 
product that is intended for parenteral administration or for wound dressings comes in 
contact with bodily fluids, must be sterilized prior to application. The most frequently used 
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sterilization methods are autoclaving, EO and gamma irradiation. The choice of sterilization 
method depends on the intended application. In vitro biocompatibility using newly 
developed chitosan wound dressings should be measured at the cellular and molecular 
level. These assays measure cytotoxicity, genotoxicity and skin irritation. In vitro model 
systems have made significant contributions to our understanding of the mechanisms of 
toxicity and carcinogenicity. They are indispensable resources to determine toxicology and 
identify potentially toxic compounds in chitosan wound dressings for human health risk 
assessment.  
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